https://prabadinews.com/
  • October 8, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

IsaKRD Induction Achieves 95% Response Rate in Multiple Myeloma

IsaKRD Induction Achieves 95% Response Rate in Multiple Myeloma

New data reveals isatuximab-based therapy achieves high MRD-negativity rates in newly diagnosed multiple myeloma.

administrator

Related Articles